Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responsesDavid Avigan, Baldev Vasir, Jianlin Gong, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 30, 2017
DCOne as an Allogeneic Cell-based Vaccine for Multiple MyelomaRebecca Karp Leaf, Dina Stroopinsky, Athalia R Pyzer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Leukemia Research|April 18, 2025
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantationBrandon J Aubrey, Traci Blonquist, Malgorzata McMasters, et al.
Hemasphere|August 21, 2025
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Anna Pula, et al.
Blood|October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2017
Increased Foxp3<sup>+</sup>Helios<sup>+</sup> Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T CellsYi-Bin Chen, Yvonne A Efebera, Laura Johnston, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>Eleni Anastasiadou, Anita G Seto, Xuan Beatty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responsesDavid Avigan, Baldev Vasir, Jianlin Gong, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 30, 2017
DCOne as an Allogeneic Cell-based Vaccine for Multiple MyelomaRebecca Karp Leaf, Dina Stroopinsky, Athalia R Pyzer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2010
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Jacalyn Rosenblatt, Zekui Wu, Baldev Vasir, et al.
Blood|June 7, 2015
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphomaSalvia Jain, Dina Stroopinsky, Li Yin, et al.
Leukemia Research|April 18, 2025
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantationBrandon J Aubrey, Traci Blonquist, Malgorzata McMasters, et al.
Hemasphere|August 21, 2025
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplantBenjamin A Derman, Jennifer Cooperrider, Anna Pula, et al.
Blood|October 30, 2010
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myelomaJacalyn Rosenblatt, Baldev Vasir, Lynne Uhl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2017
Increased Foxp3<sup>+</sup>Helios<sup>+</sup> Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T CellsYi-Bin Chen, Yvonne A Efebera, Laura Johnston, et al.
Leukemia & Lymphoma|November 18, 2022
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 studyJohn Kuruvilla, Philippe Armand, Mehdi Hamadani, et al.
Pageof 12